Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pneumo 14
- Development stage
- Unknown
- Lead developer
- Abbott
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pneumo 14 is a 14-valent pneumococcal conjugate vaccine (PCV-14) designed to provide active immunization against infections caused by Streptococcus pneumoniae. It contains purified capsular polysaccharides from 14 different serotypes of S. pneumoniae, each conjugated to a carrier protein to enhance immunogenicity. The vaccine is indicated for the prevention of invasive pneumococcal diseases such as pneumonia, meningitis, and bacteremia in children over six weeks of age. By combining bacterial polysaccharides with a protein carrier, the immune response is improved compared to non-conjugated polysaccharide vaccines[6]. This approach helps protect against severe diseases caused by multiple strains of S. pneumoniae.
- Brand names
- PneumoShield 14PneumoShield14PneumoShield-14
- Other names
- PCV-14PCV14PCV 1414-valent pneumococcal conjugate vaccine
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on Pneumo 14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pneumo 14.